23 results
Myelodysplastic Syndrome (MD) - Diagnosis and Management Summary
myelo (marrow) -dys- (abnormal) -plastic (shape) = funny-shaped cells
Myelodysplastic Syndrome ... marrow) -dys- (abnormal ... only curative treatment ... #treatment #hematology ... #oncology
Polyarteritis Nodosa (PAN) - Vasculitis Management Algorithm - ACR/VF 2021 Guidelines
 • Severe Disease → Remission
Nodosa (PAN) - Vasculitis ... Management Algorithm ... Therapy; high-dose oral ... #Management #Treatment ... Guidelines #algorithm #rheumatology
Classification of Tumor Lysis Syndrome (TLS) and Treatment of Metabolic Abnormalities of TLS
Laboratory TLS:
 • Uric
of Tumor Lysis Syndrome ... upper limit of normal ... #TumorLysis #Syndrome ... TLS #diagnosis #management ... #oncology
Eosinophilic Granulomatosis with Polyangiitis (EGPA) - ANCA Vasculitis Management Algorithm - ACR/VF 2021 Guidelines
 • Active
(EGPA) - ANCA Vasculitis ... Management Algorithm ... High-Dose Daily Oral ... #Management #Treatment ... Guidelines #algorithm #rheumatology
Giant Cell Arteritis (GCA) - Vasculitis Management Algorithm - ACR/VF 2021 Guidelines
 • Visual Symptoms/Loss or
Arteritis (GCA) - Vasculitis ... Management Algorithm ... Arteritis #GCA #Vasculitis ... #Management #Treatment ... Guidelines #algorithm #rheumatology
Behçet's Syndrome
Systemic disease associated with inflammation of multiple organs, small-vessel vasculitis and large-vessel vasculopathy
Epidemiology:
 • Young
, small-vessel vasculitis ... panuveitis, retinal vasculitis ... Arthritis, AS Treatment ... #diagnosis #management ... signs #symptoms #rheumatology
Differentiation Syndrome in APML
Epidemiology:
 • Incidence: common in APL (2-48% depending on the study)
 • Triggers:
Differentiation Syndrome ... Triggers: ATRA treatment ... 500 mg QD until normal ... APML #diagnosis #management ... #hematology #oncology
Patient risk stratification algorithm for the treatment of cancer-associated thrombosis.

Currently, edoxaban and rivaroxaban are the only
algorithm for the treatment ... direct-acting oral ... direct-acting oral ... Anticoagulation #Management ... #Hematology #Oncology
Aplastic Anemia - Overview

Who?
• M = F
• 3 peaks:	1) Childhood	2) 15-25 years	3) >60 years

What?
• Aplastic anemia
(MDS) (normal or ... megakaryocytes and a normal ... aplastic anemia Treatment ... Aplastic #Anemia #oncology ... #management
Paraproteinemias

Entities That Can Feature A Monoclonal Protein/M Component:
• MM
• WM
• MGUS
• MGCS
• MGRS
• Splenic Marginal Zone
Autoimmunity: • -MM/WM: Vasculitis ... Cryoglobulinemic, Hypo/normo-complementemic ... Hypergammaglobulinemic macular Vasculitis ... Paraproteinemias #Hematology ... Differential #Diagnosis #Oncology